Cladribine is a safe and effective treatment for highly active relapsing-remitting multiple sclerosis

被引：0
|
作者：
Suslak, T. [1 ]
Macdougall, N. [2 ]
Murray, L. [1 ]
机构：
[1] NHSGGC, Glasgow, Lanark, Scotland
[2] NHSGGC, NHSL, Glasgow, Lanark, Scotland
来源：
MULTIPLE SCLEROSIS JOURNAL | 2020年 / 26卷 / 3_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P0309
引用
收藏
页码：269 / 269
页数：1
相关论文
共 50 条
  • [11] Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands
    Renée Else Michels
    Maria de Fransesco
    Koshu Mahajan
    Gerald J. D. Hengstman
    Krijn M. H. Schiffers
    Sangeeta Budhia
    Gerard Harty
    Marieke Krol
    Applied Health Economics and Health Policy, 2019, 17 : 857 - 873
  • [12] Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands
    Michels, Renee Else
    de Fransesco, Maria
    Mahajan, Koshu
    Hengstman, Gerald J. D.
    Schiffers, Krijn M. H.
    Budhia, Sangeeta
    Harty, Gerard
    Krol, Marieke
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2019, 17 (06) : 857 - 873
  • [13] Clinical experience with cladribine in patients with relapsing-remitting multiple sclerosis
    Hodgkinson, S.
    Lizak, N.
    Butler, E.
    Lechner-Scott, J.
    Slee, M.
    McCombe, P.
    Shaw, C.
    Skibina, O.
    Vucic, S.
    Shuey, N.
    Barnett, M.
    Parratt, J.
    Butzkueven, H.
    Jack, D.
    Fabris, J.
    Kalincik, T.
    Jokubaitis, V. G.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (09) : NP64 - NP65
  • [14] Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing-remitting multiple sclerosis is effective and safe
    Alcala, Carmen
    Gascon, F.
    Perez-Miralles, Francisco
    Dominguez, J. A.
    Gil-Perotin, S.
    Casanova, B.
    JOURNAL OF NEUROLOGY, 2019, 266 (03) : 726 - 734
  • [15] Efficacy of fingolimod in patients with highly active relapsing-remitting multiple sclerosis
    Derfuss, T.
    Bergvall, N. K.
    Sfikas, N.
    Tomic, D. L.
    CURRENT MEDICAL RESEARCH AND OPINION, 2015, 31 (09) : 1687 - 1691
  • [16] Correction to: Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands
    Renée Else Michels
    Maria De Francesco
    Koshu Mahajan
    Gerald J. D. Hengstman
    Krijn M. H. Schiffers
    Sangeeta Budhia
    Gerard Harty
    Marieke Krol
    Applied Health Economics and Health Policy, 2020, 18 : 141 - 141
  • [17] Cladribine Tablets for Relapsing-Remitting Multiple Sclerosis: A Clinician's Review
    Giovannoni, Gavin
    Mathews, Joela
    NEUROLOGY AND THERAPY, 2022, 11 (02) : 571 - 595
  • [18] How effective is intravenous immunoglobulin for the treatment of relapsing-remitting multiple sclerosis?
    Cohen, Jeffrey A.
    NATURE CLINICAL PRACTICE NEUROLOGY, 2008, 4 (11): : 588 - 589
  • [19] Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis
    Hersh, Carrie M.
    Cohen, Jeffrey A.
    IMMUNOTHERAPY, 2014, 6 (03) : 249 - 259
  • [20] Ocrelizumab for the treatment of relapsing-remitting multiple sclerosis
    Menge, Til
    Dubey, Divyanshu
    Warnke, Clemens
    Hartung, Hans-Peter
    Stuve, Olaf
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2016, 16 (10) : 1131 - 1139
12345